These innovative agents represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://poppyasdl497729.review-blogger.com/60528209/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide